XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Basis of Presentation (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 01, 2019
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net loss   $ 29,219,262 $ 32,350,828  
Working capital   107,500,000    
Retained earnings (accumulated deficit)   (649,645,698)   $ (620,426,436)
Cash, cash equivalents, and short-term investments   128,000,000    
Long-term investments   8,700,000    
Proceeds from issuance of stock   $ 907,330 $ 0  
Geneos Therapeutics, Inc.        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Non-controlling interest   39.00%    
VGX Animal Health, Inc        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Non-controlling interest   15.00%    
Common Stock | Sales Agreement        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Stock sales agreement, remaining authorized sales amount   $ 71,100,000    
Proceeds from issuance of stock   907,000   $ 29,200,000
6.50% Convertible Senior Notes Due 2024 | Convertible Debt        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Proceeds from issuance of debt $ 75,700,000 75,700,000    
Principal amount $ 78,500,000.0 $ 78,500,000    
Debt instrument, interest rate, stated percentage   6.50%